03/03/2008 - Newron Pharmaceuticals S.p.A. (“Newron”, SWX: NWRN), a research and development company focused on novel CNS and pain therapies, and Hunter-Fleming Ltd., a private UK bio-pharmaceutical company developing new medicines to treat neurodegenerative and inflammatory disorders, today announced that Hunter-Fleming has received a recommendation from the independent Data Safety Monitoring Board (DSMB) to continue a Phase II safety and tolerability study with HF0220 in patients with Alzheimer’s disease (AD). The recommendation is based on the results of an interim review of the study being undertaken by Hunter-Fleming. 
On February 9, 2008, Newron signed an agreement to acquire 100% of the issued share capital of Hunter-Fleming. The Phase IIa multi-centre, double blind placebo controlled, biomarker trial includes 40 patients in study centres in the UK and Sweden, who are treated for 28 days at different doses of HF0220... [PDF] Newron's Press Release -
